ANI Pharmaceuticals (ANIP) – Investment Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for ANI Pharmaceuticals (NASDAQ: ANIP):

• 12/29/2025 – ANI Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – ANI Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – ANI Pharmaceuticals was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
• 12/9/2025 – ANI Pharmaceuticals is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $100.00 price target on the stock.
• 12/8/2025 – ANI Pharmaceuticals had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – ANI Pharmaceuticals had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – ANI Pharmaceuticals had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – ANI Pharmaceuticals had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/10/2025 – ANI Pharmaceuticals was upgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “buy (b-)” rating.
• 11/10/2025 – ANI Pharmaceuticals had its price target raised by analysts at Guggenheim from $114.00 to $115.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, Director Patrick D. Walsh sold 8,643 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $86.88, for a total value of $750,903.84. Following the completion of the transaction, the director directly owned 61,405 shares in the company, valued at approximately $5,334,866.40. This represents a 12.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chad Gassert sold 14,642 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the sale, the senior vice president directly owned 158,584 shares of the company’s stock, valued at $14,125,076.88. The trade was a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 28,001 shares of company stock worth $2,446,934. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.